The new therapeutic strategy using heparan sulfate against skin ulcer

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K09068
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 55060:Emergency medicine-related
• Research Institution: Gifu University
• Principal Investigator: Ogura Shinji 岐阜大学, 大学院医学系研究科, 教授 (30185566)
• Co-Investigator(Kenkyū-buntansha): 岡田 英志 岐阜大学, 大学院医学系研究科, 准教授 (30402176) ; 富田 弘之 岐阜大学, 大学院医学系研究科, 准教授 (50509510) ; 鈴木 昭夫 岐阜大学, 医学部附属病院, 准教授 (80775148)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: 線維芽細胞増殖因子 / 重症感染症 / ヘパラン硫酸

Outline of Final Research Achievements

Treatment of severe soft tissue injuries with fibroblast growth factor (FGF) is often complicated by the fact that FGF requires heparan sulfate to exert its effects. In this study, we investigated whether heparan sulfate is involved in skin injury healing. Mice with skin puncture injuries were created and divided into an untreated group, a trafermin spray group, a heparan sulfate-applied group, and a combined trafermin spray and heparan sulfate-applied treatment group. After injury creation, we compared the closure rate of the injured area by naked eye, and confirmed that the closure rate was higher in the combined treatment group. Therefore, a prospective, randomized, controlled pilot study was conducted, showing that the combination of bFGF and heparin may promote wound healing more effectively than bFGF alone.

Free Research Field

救急・集中治療

Academic Significance and Societal Importance of the Research Achievements

皮膚損傷を早期に治療し、患者の離床を早める可能性があるという点からも社会的意義の大きい研究であると考えられる。